首页|基于网络药理学及分子对接与实验验证苗药抑癌汤经WNT/β-catenin信号通路抑制小细胞肺癌增殖的作用机制

基于网络药理学及分子对接与实验验证苗药抑癌汤经WNT/β-catenin信号通路抑制小细胞肺癌增殖的作用机制

扫码查看
目的 运用网络药理学及分子对接技术挖掘并预测苗药抑癌汤(Miao-Yi-Ai-Tang,MYAT)治疗小细胞肺癌(Small cell lung cancer,SCLC)的作用靶点及相关信号通路,并通过细胞及动物实验验证其作用机制,为基础实验及临床应用提供理论依据。方法 从TCMSP数据库获取MYAT有效成分,并结合PubMed、Swiss Target Prediction及Uniprot数据库获取潜在靶点;通过DrugBank、Genecards、OMIM、TTD数据库收集SCLC相关基因,通过Venny 2。1平台获取MYAT和SCLC的交集基因后导入STRING数据库,构建蛋白质相互作用网络(Protein-protein interaction,PPI),运用Cytoscape 3。9。1 软件进行可视化分析,利用Metascape数据库进行GO富集分析及KEGG通路分析,预测MYAT治疗SCLC的直接作用靶点及信号通路;使用AutoDock Tools 1。5。7软件进行分子对接验证两者之间的紧密联系。通过细胞学实验验证,培养细胞加入MYAT处理并使用qPCR检测β-catenin、AXIN、c-myc的表达,Western blot检测细胞中β-catenin的表达;动物实验建立肺癌NCI-H446皮下移植瘤模型,观察MYAT对肿瘤生长的影响。结果 共获得MYAT有效成分65个,SCLC基因1368个,MYAT与SCLC交集基因260个,富集分析显示与癌症通路、PD-L1/PD-1通路、NF-κB通路、Wnt等信号通路有关。分子对接验证结果显示,其有效活性成分与核心靶点蛋白的结合能均<0 kJ·mol-1,说明蛋白可与活性成分自发结合且稳定性较好。细胞实验显示MYAT组β-catenin、c-myc及AXIN mRNA表达量均显著下调(P<0。05)。动物实验显示:MYAT能明显抑制肿瘤在体内的生长。结论 苗药抑癌汤可通过Wnt/β-catenin信号通路抑制小细胞肺癌增殖。
Based on Network Pharmacology and Molecular Docking and Experimental Verification of the Mechanism of Miao-Yi-Ai-Tang Inhibiting the Proliferation of Small Cell Lung Cancer through WNT/β-Catenin Signaling Pathway
Objective To use network pharmacology to mine and predict the targets and related signaling pathways of Miaoyao Yiai Tang(Miao-Yi-Ai-Tang,MYAT)in the treatment of small cell lung cancer(SCLC).And animal experiments to verify its mechanism of action,to provide a theoretical basis for basic experiments and clinical applications.Methods The active ingredients of MYAT were obtained from the TCMSP database,combined with PubMed data,Swiss Target Prediction database and Uniprot database to obtain potential targets;SCLC-related genes were collected through the DrugBank database,Genecards database,OMIM database and TTD database,and the Venny 2.1 platform After obtaining the intersection genes of MYAT and SCLC,import them into the STRING database,construct a protein-protein interaction(PPI)network,use Cytoscape 3.9.1 software for visual analysis,and use Metascape database for GO enrichment analysis and KEGG pathway analysis,to predict the direct action target and signaling pathway of MYAT in the treatment of SCLC.Using AutoDock Tools 1.5.7 software for molecular docking to verify the close relationship between the two.For cytological experiment verification,the cultured cells were treated with MYAT and the expression of β-catenin,AXIN,c-myc was detected by qPCR,and the expression of β-catenin in the cells was detected by Western blot;animal experiments were established to establish a subcutaneous xenograft tumor model of lung cancer NCI-H446,to observe the effect of MYAT on tumor growth.Results A total of 65 effective components of MYAT,1368 SCLC genes,and 260 MYAT-SCLC intersection genes were obtained.Enrichment analysis showed that they were related to cancer pathways,PD-L1/PD-1 pathways,NF-κB pathways,Wnt and other signaling pathways.The results of molecular docking validation showed that the binding energies of active components and core target proteins were all<0 kJ·mol-1,which indicated that the protein could spontaneously bind to active components and be stable.Cell experiments showed that the expression levels of β-catenin,c-myc and AXIN mRNA were significantly down-regulated in the MYAT group(P<0.05).Animal experiments show that:MYAT can significantly inhibit the growth of tumors in vivo.Conclusion Miao-Yi-Ai-Tang can inhibit the proliferation of small cell lung cancer through Wnt/β-catenin signaling pathway.

Miao-Yi-Ai-TangNetwork pharmacologyMolecular dockingWnt/β-catenin signaling pathwaySmall cell lung cancer(SCLC)NCI-H446 cells

陈珊、李波、葛正行、谭韬、张军、余梅、龚香群

展开 >

贵州中医药大学第二临床医学院 贵州 550002

贵州中医药大学第二附属医院 贵州 550001

苗药抑癌汤 网络药理学 分子对接 Wnt/β-catenin信号通路 小细胞肺癌(SCLC) NCI-H446细胞

2024

世界科学技术-中医药现代化
中科院科技政策与管理科学研究所,中国高技术产业发展促进会

世界科学技术-中医药现代化

CSTPCD北大核心
影响因子:1.175
ISSN:1674-3849
年,卷(期):2024.26(7)